Catherine E White

US Patent:

20170369507, Dec 28, 2017

Filed:

Dec 1, 2015

Appl. No.:

15/532549

Inventors:

- Rahway NJ, US
Stephane L. Bogen - Rahway NJ, US
Matthew L. Childers - Boston MA, US
Francesc Xavier Fradera Llinas - Boston MA, US
Michael J. Ellis - Boston MA, US
Sara Esposite - Neptune NJ, US
Qingmei Hong - Kenilworth NJ, US
Chunhui Huang - Kenilworth NJ, US
Alexander J. Kim - Rahway NJ, US
John W. Lampe - Cary NC, US
Michelle R. Machacek - Boston MA, US
Daniel R. McMasters - Boston MA, US
Ryan D. Otte - Boston MA, US
Michael H. Reutershan - Boston MA, US
Nunzio Sciammetta - Boston MA, US
Patrick Pengcheng Shao - Kenilworth NJ, US
David L. Sloman - Boston MA, US
Feroze Ujjainwalla - Kenilworth NJ, US
Catherine White - Boston MA, US
Zhicai Wu - Kenilworth NJ, US
Yang Yu - Kenilworth NJ, US
Kake Zhao - Kenilworth NJ, US
Craig R. Gibeau - Boston MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 498/08
C07D 471/04
C07D 498/10
C07D 471/08
A01N 43/00

Abstract:

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.